A 62-year-old with nonsevere CDI had symptom resolution after fidaxomicin. To reduce recurrence risk further in high-risk patients, which adjunct is c...

Question

A 62-year-old with nonsevere CDI had symptom resolution after fidaxomicin. To reduce recurrence risk further in high-risk patients, which adjunct is considered?

Accepted Answer

Bezlotoxumab infusion during antibiotic therapy

Answer

Rifaximin monotherapy

Answer

Probiotics only

Answer

Prolonged IV vancomycin

Answer

No therapy reduces recurrence

us-abim MCQ (SBA): CDI (Recurrence Prevention Adjunct)

A 62-year-old with nonsevere CDI had symptom resolution after fidaxomicin. To reduce recurrence risk further in high-risk patients, which adjunct is considered?